Glaxosmithkline Biologicals Sa

Corixa Corporation

US Government As Represented by the Secretary of the Army

Infectious Disease Research Institute

Martine Marchand

Joseph D Cohen

Yves Lobet

Christian F Ockenhouse

Anjali Yadava

Guy Baudoux

Mathieu Boxus

Brigitte Colau

Steven G Reed

Yasir A Skeiky

Mark R Alderson

Normand Blais

Peter Probst

Ajay Bhatia

Rhea N Coler

Pascal Mettens

Gerald Hermann Voss

Jean-Francois Lucien Maisonneuve

Philippe Jean Gervais Ghislain Permanne

Guy Jean Marie Fernand Pierre Baudoux

Brenda Maisonneuve

Florence Bernadette Nozay

Helge Abrecht

Martine Delchambre

Nathalie Louise Mathy

Guy Jean Baudoux

Claudine Bruck

Stephane Andre Georges Godart

The present invention is directed to methods of preventing reactivation of active and latentinfections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against ainfection. The methods also provide for shortening the time course of a chemotherapeutic regimen against ainfection.

Method for preventing or treatinginfection

Fusion proteins comprising a carrier protein and a Human Rhinovirus (HRV) peptide, and immunogenic compositions containing such fusion proteins.

Immunogenic rhinovirus peptides

[object Object]

The disclosure provides immunogenic compositions comprising human picornavirus peptides derived from structural proteins of the virus, constructs comprising the peptides, the peptides themselves and their use in the prevention of picornavirus infection and disease. Particular peptides from VP4 and VP1 are disclosed.

Vaccine

The present invention relates to a novel hybrid/fusion protein derived from the CS protein of(), methods for preparing and purifying the same, its use in medicine, particularly in the prevention of malarial infections, for example those caused by, compositions/vaccines containing the protein or antibodies against the protein such as monoclonal or polyclonal antibodies and use of the same, particularly in therapy. The invention also extends to lipoprotein particles of said hybrid protein and formulations/vaccines comprising the same and use thereof. In particular it relates to an immunogenic hybrid fusion protein comprising: a. at least one repeat unit derived from the repeating region of a type I circumsporozoite protein of b. at least one repeat unit derived from the repeating region of a type II circumsporozoite protein of, and surface antigen S derived from Hepatitis B virus, or a fragment thereof.

Vaccines for malaria

The present invention relates to a novel lipoprotein particle, methods for preparing and purifying the same, its use in medicine, particularly in the prevention of malarial infections, compositions/vaccines containing the particle or antibodies against the protein particle such as monoclonal or polyclonal antibodies and use of the same, particularly in therapy. In particular it relates to an immunogenic protein particle comprising the following monomers:

The present invention relates to a novel lipoprotein particle, methods for preparing and purifying the same, its use in medicine, particularly in the prevention of malarial infections, compositions/vaccines containing the particle or antibodies against the protein particle such as monoclonal or polyclonal antibodies and use of the same, particularly in therapy. Furthermore, particles with the specific ratio can be prepared by employing yeast,or. In particular it relates to an immunogenic protein particle comprising the following monomers:

The present invention relates to compositions comprising proteins or polynucleotides ofsp., in particular combinations of proteins or polynucleotides encoding them, and methods for the use of the proteins or polynucleotides in the treatment, prevention and diagnosis ofinfection.

Vaccines against chlamydial infection

This invention relates to novel HIV polypeptide and polynucleotide fusions of Gag, Pol and Nef which are useful in immunogenic compositions and vaccines. The invention relates in particular to a polypeptide which comprises Nef or an immunogenic fragment thereof, and p17 Gag and/or p24 Gag or immunogenic fragments thereof, wherein when both p17 and p24 Gag are present there is at least one HIV antigen or immunogenic fragment between them. The polypeptide may also comprise Pol or RT or an immunogenic fragment thereof.

Vaccine for prevention and treatment of HIV-infection

Growing community of inventors

Rixensart, Belgium

Martine Marchand